Abilify Lawsuit – Recalls & Settlements
After coming to the market in 2002, Abilify (aripiprazole) has been the subject of lawsuits from across the United States for its marketing and from injured individuals claiming that Abilify has caused them to engage in a wide range of compulsive behaviors, including: compulsive gambling, binge eating, and hypersexuality.
Often, the behaviors stemming from Abilify may go unnoticed by patients as they may not recognize their changed behavior as abnormal.
Gambling Addiction (Compulsive Gambling)
Dangerous Spending (Compulsive Spending)
Overeating (Compulsive Eating)
Dangerous or Risky Sexual Behavior (Hypersexuality)
Theft, Stealing or Shoplifting
If you suspect that you or a loved one may have suffered because of Abilify, contact our office.
Drug and device manufacturers are responsible for informing the public and potential users of their products about the risks and potential side effects associated with their product. When a manufacturer fails to do this, they can and should be held responsible for the harm that their negligence causes.
Abilify Lawsuit & Settlements Background
According to Court documents, Abilify’s manufacturers, Otsuka Pharmaceutical and Bristol-Myers Squibb, did not properly test the drug and failed to accurately represent the potential benefits of the drug, in an effort to encourage doctors to prescribe their product for uses that are not approved by the FDA.
Additional claims allege that the manufacturers were negligent in the development of Abilify and that they worked to hide evidence from government regulators and the public.
For over a decade, the manufacturers of Abilify have faced litigation for damages people have suffered as a result of their drug. Below you can find a brief summary of some major settlements and events.
- 2005: Bristol-Myers Squibb, facing allegations from the U.S. government that the company marketed Abilify to elderly patients and children for uses that were not approved by the FDA. To settle these allegations, Bristol-Myers Squibb agreed to pay $515 million.
- 2008: Otsuka Pharmaceutical, facing allegations from the U.S. government that the company targeted child psychiatrists and nursing homes for marketing of Abilify uses that were not approved by the FDA. Otsuka Pharmaceutical agreed to pay $4 million.
- 2016: Bristol-Myers Squibb, faced allegations from numerous governments for, again, promoting “off-label” uses of Abilify and misrepresenting clinical studies related to the drug. To settle the claims in the state of California, they paid $30 million.
Abilify Side Effects & Injuries
Side effects related to Abilify have been linked to compulsive behavior related disorders including, but not limited to, pathological gambling, eating, shopping, and sex. The behaviors have been shown to at almost the same time as the patient starts taking Abilify and stops when the patient no longer is taking Abilify.
Research published in the British Journal of Psychology found a connection between Abilify and increased risk of compulsive gambling. This risk existed regardless of the user’s background relationship with gambling. Additional research from the National Institutes of Health raised increased concern about the relationship between taking Abilify and extreme sexual desires. Regarding hypersexuality, again the user’s background behavior, or propensity for risky sexual behavior, was not a factor.
The FDA lists the following common side effects for Abilify:
|Common Abilify Side Effects|
|Blurred Vision||Weight Gain|
|Constipation||Feeling the Urge to Move Constantly|
Abilify (aripiprazole) Drug Background
In May 2016, the federal Food and Drug Administration (FDA) issued a drug safety communication regarding Abilify (aripiprazole). This communication required that packaging for Abilify by updated to include warnings for doctors and patients about the potential risk of the compulsive and uncontrollable behaviors, gambling, binge eating, hypersexuality, etc., that can arise while the patient is taking the medication.
According to the Food and Drug Administration (FDA), Abilify (aripiprazole) is approved for use in the treatment of certain mental disorders, these include: schizophrenia, bipolar disorder, Tourette’s disorder, irritability associated with autistic disorder, and with antidepressants in the treatment of depression.
Abilify is an atypical antipsychotic. Unlike other drugs in its class, Abilify only partially blocks the activity of dopamine receptors in the brain.
What Compensation Can I Expect?
Mass Tort litigations are complex and recoveries change for every client. With that said, some of the damages that will be investigated and potentially pursued against the drug manufacturer(s) include:
- Medical expenses, both past and future, related to Abilify injuries.
- Mental pain and suffering, both past and future, as resulted from Abilify.
- Wage losses that stem from use of Abilify.
- Gambling losses, if any exist, that followed from the use of Abilify.
- Reckless or excessive purchases, if any exist, resulting from Abilify use.
- Punitive damages, which are pursued, if appropriate, to punish the manufacturer and discourage them from engaging in future negligent behavior.
Abilify Recall Information
Currently, no recall has been issued for Abilify (aripiprazole).
Why You Should Pick Our Firm
Our law firm is focused on taking care of our clients and providing individual attention to every client we have. We provide one-on-one personal service to every client we represent. If you choose to hire our firm, you will feel taken care of and happy to be working directly with an experience lawyer.
Our founding attorney, Tom Ueberschaer, has been representing injured people since 1996. Along with his highly-experienced team, Tom will thoroughly investigate your case and investigate it for possible trial.